Focus: Dianthus Therapeutics is a biotech company focused on monoclonal antibody therapies for neurology and immunology indications. The company is early-stage with a pipeline concentrated on complement-mediated neurological disorders.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
5 added, 4 removed. Backfill posture.
Best fit for early-stage scientists/strategists seeking rare disease focus and hands-on impact, but financial stability and growth trajectory require due diligence.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dianthus Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dianthus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: First Tracks Biotherapeutics, Inc. (TRAX) (CIK 0002091349) — EX-99.1
EX-99.1
8-K Filing: Cyclerion Therapeutics, Inc. (CYCN) (CIK 0001755237) — EX-99.2
EX-99.2
8-K Filing: Zenas BioPharma, Inc. (ZBIO) (CIK 0001953926) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585) — EX-99.2
EX-99.2
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo